1.Inhibitory effect of arsenic trioxide on the proliferation of airway fibroblast and the expression of c-myc and c-sis in vitro
Chinese Journal of Pathophysiology 1986;0(02):-
AIM: To study the effects of arsenic trioxide (As_2O_3) on mouse airway fibroblast (FB) proliferation and expression of c-myc and c-sis in cultured FB. METHODS: The cultured FB was divided into seven groups. NS, dexamethasone (1.0 ?mol/L) and As_2O_3 at concentrations of 0.25, 0.5, 1.0, 2.0, 4.0 ?mol/L were instilled respectively into cultured FB. The effects of different concentration of As_2O_3 and dexamethasone on cell growth were observed at 1, 3, 5 and 7 day. The changes of cell cycle and the positive expression rate of c-myc and c-sis were examined by flow cytometry (FCM). RESULTS: Various concentrations of As_2O_3 significantly inhibited the proliferation of FB in vitro and showed a dose-dependent and time-dependent tendency. Data from FCM indicated that G_1-phase cell percentage increased and G_2/M-phase cell percentage decreased with the increase in As_2O_3 concentrations. The expression of c-myc and c-sis was significantly inhibited by As_2O_3 (2.0, 4.0 ?mol/L). CONCLUSION: As_2O_3 inhibits FB proliferation by downregulating the expression of c-myc and c-sis.
2.Tongxinluo protects vascular endothelial cells against ox-LDL-induced injury
Hongrong LI ; Chengcheng CHANG ; Yongying GUO ; Huixin LI ; Zhenhua JIA
Journal of Medical Postgraduates 2015;(11):1128-1132
Ob jectiev Oxidized low-density lipoprotein ( ox-LDL) induces vascular endothelial cell injury , which is one of the factors initiating atherosclerosis .This study aimed to investigate the protective effect of Tongxinluo ( TXL ) on vascular endothelial cells with ox-LDL-induced injury . Methods Human umbilical vein endothelial cells ( HUVEC ) were cultured in vitro and divided into five groups:normal control, oxidative stress injury (OSI) model, and high, medium and low dose TXL.The HUVECs were incubated with ox-LDL at the concentration of 30 mg/L for 24 hours to induce oxidative stress injury and then treated with TXL at 50, 100 and 150 mg/L for 4 hours, followed by 24 hour incubation with 30 mg/L ox-LDL added to the culture medium .The viability of the cells was detected by MTS assay, the nitric oxide (NO) content, superoxide dismutase (SOD) activity and mitochondrial membrane poten-tial ( MMP) in the cell culture supernatant were measured with respective kits , and the expressions of iNOS , MMP9, and NF-κBp65 proteins were determined by Western blot . Results The HUVECs of the OSI model group showed a significant decrease in cell via-bility compared with the normal control , ([73 .89 ±0.67] vs [100.00 ±2.23]%, P<0.01) but a remarkably increase after treated with medium and high dose TXL ([92.15 ±0.76]%and [ 97.19 ±1.45]%, P<0.01).The MMP, NO content, and SOD activity were markedly reduced in the model group (P<0.01) but elevated in the low, medium, and high dose TXL groups (P<0 .01).The expressions of the iNOS, MMP9, and NF-κBp65proteins were significantly up -regulated in the model group (P<0.01) but down reg-ulated in the low, medium, and high dose TXL groups (P<0.05).C on clusion TXL has the effects of anti-oxidation and anti-in-flammation and can protect vascular endothelial cells against ox-LDL-induced injury .
3.Diagnosis and treatment of 27 patients with redundant colon
Changping YANG ; Hongrong GUO ; Jinlin CAO ; Renrong YANG ; Haiying GUO ; Guibao LIU
International Journal of Surgery 2012;39(7):450-452,505
ObjectiveTo explore the early diagnosis and effective treatment of redundant colon,and to reduce the misdiagnosis and shorten the medical treatment time before the diagnosis.MethodsClinical data of twentyseven patients with redundant colon from February 2005 to December 2011 were retrospectively analyzed in General Surgery Department of 117th and 322th People's Liberation Army Hospital.ResultsThe clinical symptoms of 27 patients nainly as early recurrent intractable constipation,bloating,abdominal pain,weight loss and other symptoms,were likely to be in a misdiagnosis.In addition to three patients with redundant sigmoid colon concurrent reverse came to hospital emergency with surgery,twenty-four cases' symptoms persisted and came to many hospitals with medical treatment up to 32 years,diagnosed by the out-patient barium enema.After surgical resection disease bowel,7-11 months follow-up,patients abdominal distension,abdominal pain,constipation,weight loss and other systemic unwell symptoms disappeared.ConclusionThis disease is rare,we must raise the medical staff's awareness of this disease.X-ray examination with barium enema is the best way to diagnose this disease.After diagnosis,surgery is the most effective treatment.
5.Vitamin D supplementation decreases the expression of TGF-β1 in rats with asthma and thereby suppressing airway remodeling
Caiyu QIU ; Xingkun ZENG ; Hongrong GUO
Journal of Chinese Physician 2018;20(6):855-860
Objective To investigate the preventive and therapeutic effects of 1,25-(OH) 2D3 on airway remodeling in asthmatic rats,and to explore the effect of 1,25-(OH) 2D3 on the expression of transforming growth factor-β 1 (TGF-β 1) and the related mechanism between them.Methods Seventy male Sprague Dawley (SD) rats were randomly divided into seven groups:normal control group (group A,n =10),asthmatic group (group B,n =10),dexamethasone group (group C,n =10),1,25-(OH)2D3 2 μg/(kg·d) group (group D,n=10),1,25-(OH)2D3 4 μg/(kg · d) group (group E,n =10),1,25-(OH)2D3 8 μg/(kg · d) group (group F,n =10),1,25(OH)2D3 16 μg/(kg · d) group (group G,n=10).Rats were sensitized and challenged with ovalbumin (OVA) to establish the asthmatic model in B,C,D,E,F,G group respectively.Rats in group B and group C were fed with normal saline 10 ml/(kg · d) and dexamethasone 2 mg/(kg · d) before atomization.While group D-G was 1,25-(OH)2D3 intervention group,rats were fed with vitamin D 2,4,8,16 μg/(kg · d) before atomization.The number of total and different cells of the bronchoalveolar lavage fluid (BALF) from the 7 groups was counted for analysis;The change of the thickness,the area of airway wall and the number of ASMC nucleus and pulmonary tissue changes were observed by microscope.The protein and mRNA expression of TGF-β1 in the lung tissue was measured by immunochemistry and real-time polymerase chain reaction (RT-PCR).Results (1) The airway remodeling and pulmonary inflammatory exudation in the B group were significantly heavier than those in the A,C and G groups (P <0.01);and the difference between groups of different doses of vitamin D [D group (minimum dose) and G group(the maximum dose)] was statistically significant (P < 0.01).(2) The results of TGF-β1 mRNA and protein levels in rats of each group showed that the expression level of TGF-β1 mRNA and integrated option density (IOD) value in A group were significantly lower than those in other groups (P <0.01);the expression level of TGF-β1 mRNA and IOD value in B group was higher than the other groups (P <0.01);Compared with the B group,the expression level of TGF-β1 mRNA and IOD value in G group (large dose vitamin D group) was decreased,with statistically difference.Conclusions In the rat model of asthma,1,25-(OH) 2D3 may alleviate airway remodeling by regulating the expression of TGF-beta 1 and play its opposite biological effect in the prevention and treatment of asthma.
6.Effects of formyl peptide receptor 1 antagonist Boc2 on malignant biological behaviors of human lung adenocarcinoma cells under hypoxia conditions
HUANG Bo ; DING Jie ; GUO Hongrong
Chinese Journal of Cancer Biotherapy 2018;25(2):125-131
[Abstract] Objective: To investigate the effects of FPR1 (formyl peptide receptor 1) antagonist Boc2 on migration, invasion, proliferation and tumorigenicity of human lung adenocarcinoma cells under hypoxia conditions. Methods: The protein expressions of hypoxia inducible factor 1α (HIF-1α) and FPR1 in human lung adenocarcinoma A549 cells induced by hypoxia was detected by Western blotting. FPR1 antagonist Boc2 was used to treat the hypoxia-induced A549 cells in vitro. The cells were divided into three groups: control group (cultured under normoxic condition), hypoxia group and hypoxia+Boc2 treatment group. Cell scratch test, transwell matrigel invasion assay and MTT method were used to detect the migration, invasion and proliferation of each group of cells, respectively. The A549 cells of each group were inoculated into nude mice to prepare xenograft model.After 4 weeks, the nude mice were sacrificed, and the differences in average tumor volume and mass, tumor formation rate, the expression of migration-related protein-E-cadherin (E-cad) and invasion-related protein-matrix metalloproteinase 9 (MMP-9) were analyzed. Results: Hypoxia induction can promote the expression of FPR1 protein in A549 cells in a time-dependent manner (P<0.05). The results of cell experiments showed that the ability of migration, invasion and proliferation of cells in hypoxia group were significantly higher than those in control group (P<0.01); while compared with hypoxia group, Boc2 treatment significantly inhibited the migration, invasion and proliferation of A549 cells (P<0.05). The results of nude mice experiments showed that the average volume and mass of nude mice in hypoxia group were significantly higher than those in the control group (all P<0.01). But the mean volume and mass of nude mice in hypoxia+Boc2 treatment group were significantly lower than those in the hypoxia group (all P<0.01). The rate of tumor formation in nude mice of hypoxia group was 100.0% (15/ 15), which was significantly higher than 60.0% (9/15) in the control group (χ2=7.500, P=0.006) and 73.3% (11/15) in the hypoxia + Boc2 treatment group (χ2=4.615, P=0.032). The expression of E-cad and MMP-9 protein in hypoxia group was significantly higher than that in control group (P<0.01), while Boc2 treatment significantly decreased the expression of E-cad and MMP-9 protein in hypoxia group (P<0.05). Conclusions: FPR1 antagonist Boc2 can significantly inhibit the migration, invasion, proliferation and tumorigenicity of hypoxia-induced human lung adenocarcinoma A549 cells, indicating that FPR1 plays an important role in the development and progression of human lung adenocarcinoma and may become a potential target of human lung adenocarcinoma treatment.
7. Comparison of age-based clinical and abnormal immune parameters in patients with Henoch-Schönlein purpura
Na ZHANG ; Peijing GUO ; Pinli LIU ; Hongrong YANG ; Jing XIAO ; Xinpeng LI ; Jinbo HUANG ; Yizhou ZHENG
Chinese Journal of Hematology 2017;38(1):60-64
Objective:
To explore age-based clinical and immune parameters in Henoch-Schönlein purpura (HSP) to determine clinically useful markers reflecting disease characteristic.
Methods:
A cohort of 502 patients with HSP were enrolled into this retrospective study to evaluate their clinical and immune data.
Results:
Majority HSP cases occurred at age ≤14 years and showed significant immune imbalances of ESR, CD3+ cells, CD4+ cells, CD3-CD16+CD56+ cells, CD4+/CD8+ cells, IgG, IgA, IgM, IgE, complements C3/C4 and ASO in the acute phase. Compared to patients aged >14 years, symptoms of joint were more frequent at disease onset in patients aged ≤14 years (20.8%
8.The effect of SIRT3 on lung cancer cell apoptosis by regulating ROS-mediated oxidative stress under hypoxic conditions
Bo HUANG ; Jie DING ; Hongrong GUO ; Hongjuan WANG ; Jianqun XU ; Quan ZHENG
Acta Universitatis Medicinalis Anhui 2023;58(12):2045-2050,2057
Objective To investigate the effect of sirtuin 3(SIRT3)on the oxidative stress response and hypoxia inducible factor-1α(HIF-1α)expression in lung cancer cells through reactive oxygen species(ROS)under hypoxic conditions and its mechanism.Methods Human non-small cell lung cancer A549 cells were exposed to hypoxia for 0 h,12 h,24 h and 48 h.The mRNA and protein expressions of HIF-1α and SIRT3 were detected by RT-PCR and Western blot to determine the optimal time of hypoxia induction.A549 cells were divided into 5 groups:control group,hypoxia group,hypoxia+ROS inhibitor n-acetylcysteine(NAC)group,hypoxia+(SIRT3 overexpression)SIRT3-OE group and hypoxia+SIRT3-OE+NAC group.Cell proliferation was detected by MTT assay.Cell apop-tosis was detected by flow cytometry.The mRNA and protein expressions of HIF-1 α and SIRT3 in each group were detected by RT-PCR and Western blot.ROS content in each group was detected by flow cytometry.The contents of malondialdehyde(MDA),superoxide dismutase(SOD)and glutathione(GSH)in the cells of each group were detected by biochemical kits.Results The optimal induction time of hypoxia was 24 h.Compared with the control group,the apoptosis rate,SIRT3 mRNA and protein levels,SOD and GSH contents in the hypoxia group signifi-cantly decreased(P<0.01),the cell proliferation ability,HIF-1 α mRNA and protein levels,ROS and MDA con-tent in cells significantly increased(P<0.01).Compared with the hypoxia group,the apoptosis rate,SIRT3 mR-NA and protein levels,SOD and GSH contents in the hypoxia+NAC and hypoxia+SIRT3-OE groups increased(P<0.05),the cell proliferation ability,HIF-1 α mRNA and protein levels,ROS and MDA content in cells de-creased(P<0.05).Compared with the hypoxia+NAC group,the apoptosis rate,SIRT3 mRNA and protein lev-els,SOD and GSH contents in the hypoxia+SIRT3-OE+NAC group significantly increased(P<0.01),the cell proliferation ability,HIF-1 α mRNA and protein levels,ROS and MDA content in cells significantly decreased(P<0.01).Conclusion Under hypoxic conditions,SIRT3 can promote cell apoptosis and inhibit lung cancer pro-gression by mediating ROS to inhibit oxidative stress response and HIF-1 α expression in lung cancer cells.
9.A trial of arbidol hydrochloride in adults with COVID-19
Jingya ZHAO ; Jinnong ZHANG ; Yang JIN ; Zhouping TANG ; Ke HU ; Hui SUN ; Mengmeng SHI ; Qingyuan YANG ; Peiyu GU ; Hongrong GUO ; Qi LI ; Haiying ZHANG ; Chenghong LI ; Ming YANG ; Nian XIONG ; Xuan DONG ; Juanjuan XU ; Fan LIN ; Tao WANG ; Chao YANG ; Bo HUANG ; Jingyi ZHANG ; Shi CHEN ; Qiong HE ; Min ZHOU ; Jieming QU
Chinese Medical Journal 2022;135(13):1531-1538
Background::To date, there is no effective medicine to treat coronavirus disease 2019 (COVID-19), and the antiviral efficacy of arbidol in the treatment for COVID-19 remained equivocal and controversial. The purpose of this study was to evaluate the efficacy and safety of arbidol tablets in the treatment of COVID-19.Methods::This was a prospective, open-label, controlled and multicenter investigator-initiated trial involving adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patients were stratified 1:2 to either standard-of-care (SOC) or SOC plus arbidol tablets (oral administration of 200 mg per time, three times a day for 14 days). The primary endpoint was negative conversion of SARS-CoV-2 within the first week. The rates and 95% confidential intervals were calculated for each variable.Results::A total of 99 patients with laboratory-confirmed SARS-CoV-2 infection were enrolled; 66 were assigned to the SOC plus arbidol tablets group, and 33 to the SOC group. The negative conversion rate of SARS-CoV-2 within the first week in patients receiving arbidol tablets was significantly higher than that of the SOC group (70.3% [45/64] vs. 42.4% [14/33]; difference of conversion rate 27.9%; 95% confidence interval [CI], 7.7%-48.1%; P = 0.008). Compared to those in the SOC group, patients receiving arbidol tablets had a shorter duration of clinical recovery (median 7.0 days vs. 12.0 days; hazard ratio [HR]: 1.877, 95% CI: 1.151-3.060, P = 0.006), symptom of fever (median 3.0 days vs. 12.0 days; HR: 18.990, 95% CI: 5.350-67.410, P < 0.001), as well as hospitalization (median 12.5 days vs. 20.0 days; P < 0.001). Moreover, the addition of arbidol tablets to SOC led to more rapid normalization of declined blood lymphocytes (median 10.0 days vs. 14.5 days; P > 0.05). The most common adverse event in the arbidol tablets group was the elevation of transaminase (5/200, 2.5%), and no one withdrew from the study due to adverse events or disease progression. Conclusions::SOC plus arbidol tablets significantly increase the negative conversion rate of SARS-CoV-2 within the first week and accelerate the recovery of COVID-19 patients. During the treatment with arbidol tablets, we find no significant serious adverse events.Trial registration::Chinese Clinical Trial Registry, NCT04260594, www.clinicaltrials.gov/ct2/show/NCT04260594?term= NCT04260594&draw=2&rank=1